Science At BMS

Stress is a challenge in care. At #ASCO26, stop by our booth to experience a brief, accessible moment of stress relief with @thrive. #OneBMS

Join us tomorrow at #ASCO26 as Dr. Solange Peters presents Phase 2 results from ROSETTA Lung-02. @peters_solange Stop by or join the live stream from 1:21–1:27pm CDT. #LungCancer #BioNTech_Group

Join us tomorrow at #ASCO26 as Dr. Tiago Biachi de Castria presents ROSETTA CRC-203 TiP poster. @BiachiTiago Join the poster session from 9am to 12pm CDT. #GICancer #BioNTech_Group

Breakthroughs in oncology are moving fast—but access is still determining who benefits from them. On DoctoRx Unscripted, leading oncologists join Dr. Tania Small to explore what it will take to close that gap. Watch the full oncology series now: bit.ly/4tV3lkR

Nearly 70% of lung cancers are still diagnosed at an advanced stage, but science is changing what’s possible—giving some patients years of life back. Two leading oncologists join Dr. Tania Small to discuss how more patients can benefit. Watch now: bit.ly/4usEsOC

Melanoma incidence continues to rise, affecting diverse age groups. Early detection and awareness are vital for better outcomes. Hear more about the realities of melanoma: bit.ly/4tM7J5M #OneBMS #MelanomaAwarenessMonth

At #ATS2026, we're exploring the pathophysiology of #PulmonaryFibrosis, and the key role the lysophosphatidic acid (LPA-LPA1) pathway plays in epithelial cell injury, inflammation and fibrosis—all of which result in disease progression. Learn more: bit.ly/4nDzbkM #OneBMS

Endocannabinoids help regulate neuronal signaling. We’re exploring how inhibition of Fatty acid amide hydrolase (FAAH) and Monoacylglycerol lipase (MAGL) may impact endocannabinoid levels in conditions like Alzheimer’s disease. Learn more: bit.ly/4dbQ3u2 #OneBMS

Wrap up the last day of the #AACR2026 conference by stopping by the poster session to hear Dr. Jaclyn Neely’s presentation of the biomarker analyses from the RELATIVITY 104 trial. Join the session from 9am to 12pm PST #LungCancer #NSCLC

Stop by the poster session tomorrow, at #AACR2026, to hear Dr. Takekazu Aoyama’s overview of the RELATIVITY 020 clinical trial, with a focus on dose safety and efficacy. Join the session from 9am to 12pm PST. #SolidTumor

Today at #AACR2026, Dr. Igor Katsyv will present the poster Comparison of MTAP loss by IHC and MTAP homozygous deletion by NGS and DNA FISH. Stop by the poster session from 2–5pm PST. #CancerGenomics #AssayDevelopment #AACR2026

Our teams are advancing targeted protein degradation leveraging three distinct modalities: CELMoD agents, ligand-directed degraders and degrader antibody conjugates. Explore how we’re driving cancer breakthroughs: bit.ly/4cplmB5 #AACR26 #ScienceFirsthand #OneBMS

At #AACR26, Dr. Tina Cascone will present data from CheckMate 77T, exploring clinical outcomes by genomic markers and ctDNA dynamics in resectable non-small cell lung cancer (#NSCLC). Learn more: bit.ly/4dNcIia

Explore evidence-based management of Alzheimer’s disease psychosis at AAGP 2026. Dr. Amita Patel, MD, will discuss clinical recognition, differential diagnosis, and current and emerging therapeutic approaches.

Colorectal cancer (CRC) rates are increasing, with a growing trend in younger age groups. Early detection and awareness are key to helping fight CRC. Learn more about the current CRC landscape: bit.ly/4tcnseu #OneBMS #ColorectalCancerAwarenessMonth

At #ACC26, our team presented topline results from a Phase 3 trial for adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Learn more: bit.ly/4m37C3p #OneBMS

Join us at #EPA2026 to hear Dr. Correll, Dr. Hort and Dr. Vieta discuss the role of the cholinergic system in neuropsychiatric diseases, emerging therapeutic approaches and key considerations for the use of muscarinic agonists and other ACh-targeting therapies.

Fifteen years ago, the US FDA approved the first immune checkpoint inhibitor. This pivotal approval marked the beginning of a robust ongoing journey for immuno-oncology research. Learn more about the history and our hopes for the future of cancer care: bit.ly/48d0GLf

As the cardiovascular community comes together for #ACC26, learn more about our collaboration with @JNJInnovMed to spotlight the promise of factor XIa (FXIa) inhibition for patients and clinicians: bit.ly/3O0ML4a #OneBMS

Exciting science on display at #ELCC26 — a look at the Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD‑L1xVEGF‑A bispecific immunomodulator plus chemotherapy in first-line NSCLC.